ACP-211 vs BI 1569912

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

ACP-211

Developed by Acadia Pharmaceuticals

Phase 2 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT07284667 (registry estimate)

No aligned efficacy figure on record for this race.

BI 1569912

Developed by Boehringer Ingelheim

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT06280235 · Phase 2 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.

Reported efficacy

Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) (missed)

Result source: NCT06558344

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointACP-211BI 1569912
MADRS, change (acute)—Not reported-12.3 vs -12−0.3 vs placebo20 mg · wk 6 · n 74NCT06280235
10 other results
  • -10 vs -10.3 20 mg · wk 6 · n 66 · Phase 2 · primary NCT06558344
  • -19.9 vs -19.3 20 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -11.9 vs -12 10 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -10.6 vs -10.3 10 mg · wk 6 · n 36 · Phase 2 · primary NCT06558344
  • -7.8 vs -12 5 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -13.6 vs -10.3 5 mg · wk 6 · n 30 · Phase 2 · primary NCT06558344
  • -16.8 vs -19.3 5 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -5.7 vs -6.4 20 mg · wk 1.142857 · n 74 · Phase 2 · secondary NCT06280235
  • -5.9 vs -6.4 10 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235
  • -5.2 vs -6.4 5 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported34.8% vs 33.8%+1 vs placebo20 mg · wk 6 · n 66NCT06280235
5 other results
  • 15.5% vs 11.3% 20 mg · wk 1.142857 · n 71 · Phase 2 · secondary NCT06280235
  • 31.4% vs 33.8% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 10 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235
  • 20.6% vs 33.8% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 5 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235
MADRS remission—Not reported21.2% vs 19.7%+1.5 vs placebo20 mg · wk 6 · n 66NCT06280235
2 other results
  • 25.7% vs 19.7% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 8.8% vs 19.7% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

ACP-211
—Not reported
BI 1569912
-12.3 vs -12−0.3 vs placebo20 mg · wk 6 · n 74NCT06280235
10 other results
  • -10 vs -10.3 20 mg · wk 6 · n 66 · Phase 2 · primary NCT06558344
  • -19.9 vs -19.3 20 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -11.9 vs -12 10 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -10.6 vs -10.3 10 mg · wk 6 · n 36 · Phase 2 · primary NCT06558344
  • -7.8 vs -12 5 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -13.6 vs -10.3 5 mg · wk 6 · n 30 · Phase 2 · primary NCT06558344
  • -16.8 vs -19.3 5 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -5.7 vs -6.4 20 mg · wk 1.142857 · n 74 · Phase 2 · secondary NCT06280235
  • -5.9 vs -6.4 10 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235
  • -5.2 vs -6.4 5 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235

CGI-S, change (acute)

ACP-211
—Not reported
BI 1569912
—Not reported

MADRS response

ACP-211
—Not reported
BI 1569912
34.8% vs 33.8%+1 vs placebo20 mg · wk 6 · n 66NCT06280235
5 other results
  • 15.5% vs 11.3% 20 mg · wk 1.142857 · n 71 · Phase 2 · secondary NCT06280235
  • 31.4% vs 33.8% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 10 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235
  • 20.6% vs 33.8% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 5 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235

MADRS remission

ACP-211
—Not reported
BI 1569912
21.2% vs 19.7%+1.5 vs placebo20 mg · wk 6 · n 66NCT06280235
2 other results
  • 25.7% vs 19.7% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 8.8% vs 19.7% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235

Relapse (% of patients)

ACP-211
—Not reported
BI 1569912
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ACP-211: no structured comparison results are available for Major Depressive Disorder.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ACP-211: 0 of 4 rows · BI 1569912: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBI 1569912
Dropout rate
9.6%20 mga
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
7.3%10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
12.5%5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
9.6%20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
14.6%10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
17.1%5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5%20 mg
NCT04937829 · Phase 1
15%5 mg
NCT04937829 · Phase 1
Discontinued due to AEs
2.4%20 mga
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
4.9%10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5%5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
2.7%20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
4.9%10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
—20 mg
NCT04937829 · Phase 1
—5 mg
NCT04937829 · Phase 1
Serious AEs
1.2%20 mga
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
2.4%10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
2.4%10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%20 mg
NCT04937829 · Phase 1
0%5 mg
NCT04937829 · Phase 1
Most frequent reported AEs
20 mga
dizziness 8.4% (placebo 2.5%)
headache 8.4% (placebo 6.3%)
nasopharyngitis 4.8% (placebo 3.8%)
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
10 mg
headache 4.9% (placebo 6.3%)
upper respiratory tract infection 2.4% (placebo 6.3%)
dizziness 0% (placebo 2.5%)
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5 mg
headache 7.5% (placebo 6.3%)
nasopharyngitis 7.5% (placebo 3.8%)
upper respiratory tract infection 5% (placebo 6.3%)
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20 mg
headache 12.3% (placebo 7.9%)
nasopharyngitis 8.2% (placebo 3.9%)
diarrhoea 2.7% (placebo 1.3%)
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
10 mg
headache 9.8% (placebo 7.9%)
diarrhoea 4.9% (placebo 1.3%)
nasopharyngitis 4.9% (placebo 3.9%)
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5 mg
headache 14.3% (placebo 7.9%)
diarrhoea 5.7% (placebo 1.3%)
upper respiratory tract infection 5.7% (placebo 1.3%)
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20 mg
decreased appetite 5% (placebo 5.3%)
blood pressure increased 0% (placebo 0%)
constipation 0% (placebo 0%)
NCT04937829 · Phase 1
5 mg
blood pressure increased 10% (placebo 0%)
constipation 10% (placebo 0%)
headache 5% (placebo 5.3%)
NCT04937829 · Phase 1

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BI 1569912

MADRS -12.3 vs -12 placebo score @ 6wk20 mg
absolute change · score
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 10 more results
-5.7 vs -6.4 placebo score @ 1.142857wk20 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-10 vs -10.3 placebo score @ 6wk20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
-19.9 vs -19.3 placebo score @ 1wk20 mg
NCT04937829 · Phase 1
-11.9 vs -12 placebo score @ 6wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-5.9 vs -6.4 placebo score @ 1.142857wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-10.6 vs -10.3 placebo score @ 6wk10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-7.8 vs -12 placebo score @ 6wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-5.2 vs -6.4 placebo score @ 1.142857wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-13.6 vs -10.3 placebo score @ 6wk5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-16.8 vs -19.3 placebo score @ 1wk5 mg
NCT04937829 · Phase 1
MADRS 15.5% (n=71) vs 11.3% (n=71) placebo @ 1.142857wk20 mg
responder rate · % of participants
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 5 more results
34.8% (n=66) vs 33.8% (n=71) placebo @ 6wk20 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
11.1% (n=36) vs 11.3% (n=71) placebo @ 1.142857wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
31.4% (n=35) vs 33.8% (n=71) placebo @ 6wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
11.1% (n=36) vs 11.3% (n=71) placebo @ 1.142857wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20.6% (n=34) vs 33.8% (n=71) placebo @ 6wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
MADRS Remission 21.2% (n=66) vs 19.7% (n=71) placebo @ 6wk20 mg
responder rate · % of participants
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
25.7% (n=35) vs 19.7% (n=71) placebo @ 6wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
8.8% (n=34) vs 19.7% (n=71) placebo @ 6wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
SMDDS -7.1 vs -7.6 placebo score @ 1.142857wk20 mg
absolute change · score
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 5 more results
-11.1 vs -10.4 placebo score @ 4wk20 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-6.5 vs -7.6 placebo score @ 1.142857wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-11.8 vs -10.4 placebo score @ 4wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-7.4 vs -7.6 placebo score @ 1.142857wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-11.3 vs -10.4 placebo score @ 4wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACP-211's landscape · BI 1569912's landscape